Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
23.05 (1y: +24%)
Market Cap 1 B P/E(ttm) 343.90
Enterprise Value 1.15 B P/B 1.90
NUVA- NAS (USA)
NuVasive, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$23.05
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.643
NUVA's Cash to Debt is ranked lower than
73% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. NUVA: 0.643 )
NUVA' s 10-Year Cash to Debt Range
Min: 0.64   Max: No Debt
Current: 0.64
Equity to Asset 0.242
NUVA's Equity to Asset is ranked lower than
75% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. NUVA: 0.242 )
NUVA' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.88
Current: 0.24
-0.16
0.88
Interest Coverage 1.4
NUVA's Interest Coverage is ranked lower than
71% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 420.30 vs. NUVA: 1.4 )
NUVA' s 10-Year Interest Coverage Range
Min: 1   Max: No Debt
Current: 1.4
F-Score: 6
Z-Score: 1.61
M-Score: -3.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 6.00
NUVA's Operating margin (%) is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. NUVA: 6.00 )
NUVA' s 10-Year Operating margin (%) Range
Min: -27436.5   Max: 6.7
Current: 6
-27436.5
6.7
Net-margin (%) 0.5
NUVA's Net-margin (%) is ranked lower than
52% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. NUVA: 0.5 )
NUVA' s 10-Year Net-margin (%) Range
Min: -27211.5   Max: 16.4
Current: 0.5
-27211.5
16.4
ROE (%) 0.6
NUVA's ROE (%) is ranked lower than
54% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. NUVA: 0.6 )
NUVA' s 10-Year ROE (%) Range
Min: -161   Max: 18
Current: 0.6
-161
18
ROA (%) 0.3
NUVA's ROA (%) is ranked lower than
55% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. NUVA: 0.3 )
NUVA' s 10-Year ROA (%) Range
Min: -303.6   Max: 9.8
Current: 0.3
-303.6
9.8
ROC (Joel Greenblatt) (%) 12.90
NUVA's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. NUVA: 12.90 )
NUVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -369   Max: 17.3
Current: 12.9
-369
17.3
Revenue Growth (%) 10
NUVA's Revenue Growth (%) is ranked higher than
96% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NUVA: 10 )
NUVA' s 10-Year Revenue Growth (%) Range
Min: -32   Max: 276.7
Current: 10
-32
276.7
EBITDA Growth (%) 17.3
NUVA's EBITDA Growth (%) is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. NUVA: 17.3 )
NUVA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 74.7
Current: 17.3
0
74.7
EPS Growth (%) -17.3
NUVA's EPS Growth (%) is ranked higher than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. NUVA: -17.3 )
NUVA' s 10-Year EPS Growth (%) Range
Min: -55.8   Max: 22.4
Current: -17.3
-55.8
22.4
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

NUVA Guru Trades in Q2 2012

PRIMECAP Management 496,000 sh (+7.13%)
Chuck Royce 618,400 sh (+3.07%)
Vanguard Health Care Fund 1,680,103 sh (unchged)
Mario Gabelli 17,000 sh (unchged)
Jim Simons 213,005 sh (-20.9%)
Steven Cohen 17,707 sh (-52.2%)
» More
Q3 2012

NUVA Guru Trades in Q3 2012

Ken Fisher 345,302 sh (New)
Jim Simons 266,000 sh (+24.88%)
Mario Gabelli 17,000 sh (unchged)
Chuck Royce 618,400 sh (unchged)
PRIMECAP Management 496,000 sh (unchged)
Vanguard Health Care Fund 1,628,303 sh (-3.08%)
Steven Cohen 3,166 sh (-82.12%)
» More
Q4 2012

NUVA Guru Trades in Q4 2012

Joel Greenblatt 78,542 sh (New)
Paul Tudor Jones 12,900 sh (New)
Steven Cohen 671,889 sh (+21122%)
Mario Gabelli 32,000 sh (+88.24%)
PRIMECAP Management 669,000 sh (+34.88%)
Ken Fisher 464,375 sh (+34.48%)
Jim Simons 348,588 sh (+31.05%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Chuck Royce Sold Out
» More
Q1 2013

NUVA Guru Trades in Q1 2013

Paul Tudor Jones 19,100 sh (+48.06%)
Mario Gabelli 45,700 sh (+42.81%)
Joel Greenblatt 108,240 sh (+37.81%)
PRIMECAP Management 719,000 sh (+7.47%)
Vanguard Health Care Fund 1,628,303 sh (unchged)
Ken Fisher 355,475 sh (-23.45%)
Steven Cohen 424,049 sh (-36.89%)
Jim Simons 17,900 sh (-94.86%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 37.81%0.03%$15.46 - $21.31 $ 23.127%108240
Mario Gabelli 2013-03-31 Add 42.81%$15.46 - $21.31 $ 23.127%45700
Joel Greenblatt 2012-12-31 New Buy0.07%$12.65 - $23.01 $ 23.158%78542
PRIMECAP Management 2012-12-31 Add 34.88%$12.65 - $23.01 $ 23.158%669000
Mario Gabelli 2012-12-31 Add 88.24%$12.65 - $23.01 $ 23.158%32000
Mario Gabelli 2012-03-31 Add 21.43%$11.35 - $17.56 $ 23.160%17000
Vanguard Health Care Fund 2011-06-30 Reduce -21.13%0.06%$24.98 - $34.65 $ 23.1-25%1680103
Mario Gabelli 2011-06-30 Add 33.33%$24.98 - $34.65 $ 23.1-25%12000
Mario Gabelli 2011-03-31 Reduce -69.49%$24.75 - $30.26 $ 23.1-15%9000
Vanguard Health Care Fund 2010-12-31 New Buy0.3%$22.25 - $37.36 $ 23.1-16%2130103
PRIMECAP Management 2010-12-31 Add 41.15%0.01%$22.25 - $37.36 $ 23.1-16%425000
Mario Gabelli 2010-12-31 Add 247.06%$22.25 - $37.36 $ 23.1-16%29500
PRIMECAP Management 2010-06-30 Add 33.64%0.01%$35.24 - $44.86 $ 23.1-43%301100
Mario Gabelli 2010-06-30 Reduce -75.07%$35.24 - $44.86 $ 23.1-43%9000
George Soros 2010-06-30 Sold Out $35.24 - $44.86 $ 23.1-43%0
PRIMECAP Management 2010-03-31 New Buy0.02%$27.48 - $46.42 $ 23.1-34%225300
George Soros 2010-03-31 New Buy$27.48 - $46.42 $ 23.1-34%5400
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about NuVasive, Inc.

Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure
April 11, 2013
Ken Fisher - Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure
With a market cap of $9.24 billion, NuVasive Inc. (NUVA) is the minimally invasive spine surgery company with a portfolio of 80 products used to revolutionize the way surgeons work with spine problems. GuruFocus research shows the stock is up 31% over the last 12 months, with the current share price at $21.56. The company stock has a P/E ratio of 275.5, a P/B ratio of 1.74 and a P/S ratio of 1.48. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 343.90
NUVA's P/E(ttm) is ranked lower than
57% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. NUVA: 343.90 )
NUVA' s 10-Year P/E(ttm) Range
Min: 14.88   Max: 347.16
Current: 343.9
14.88
347.16
P/B 1.90
NUVA's P/B is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. NUVA: 1.90 )
NUVA' s 10-Year P/B Range
Min: 0.97   Max: 10.85
Current: 1.9
0.97
10.85
P/S 1.70
NUVA's P/S is ranked higher than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NUVA: 1.70 )
NUVA' s 10-Year P/S Range
Min: 0.86   Max: 10.64
Current: 1.7
0.86
10.64
PFCF 11.40
NUVA's PFCF is ranked higher than
78% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. NUVA: 11.40 )
NUVA' s 10-Year PFCF Range
Min: 6.98   Max: 161.37
Current: 11.4
6.98
161.37
EV-to-EBIT 31.3
NUVA's EV-to-EBIT is ranked lower than
52% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. NUVA: 31.3 )
NUVA' s 10-Year EV-to-EBIT Range
Min: 20.8   Max: 156.1
Current: 31.3
20.8
156.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 8.4
NUVA's Price/Net Current Asset Value is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. NUVA: 8.4 )
NUVA' s 10-Year Price/Net Current Asset Value Range
Min: 4.3   Max: 34.1
Current: 8.4
4.3
34.1
Price/Tangible Book 3.6
NUVA's Price/Tangible Book is ranked higher than
68% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. NUVA: 3.6 )
NUVA' s 10-Year Price/Tangible Book Range
Min: 2.2   Max: 13.8
Current: 3.6
2.2
13.8
Price/DCF (Projected) 1.8
NUVA's Price/DCF (Projected) is ranked higher than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. NUVA: 1.8 )
NUVA' s 10-Year Price/DCF (Projected) Range
Min: 1.2   Max: 25.1
Current: 1.8
1.2
25.1
Price/Median PS Value 0.4
NUVA's Price/Median PS Value is ranked lower than
56% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. NUVA: 0.4 )
NUVA' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 2
Current: 0.4
0.2
2
Price/Graham Number 8.2
NUVA's Price/Graham Number is ranked higher than
93% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. NUVA: 8.2 )
NUVA' s 10-Year Price/Graham Number Range
Min: 1.9   Max: 13.1
Current: 8.2
1.9
13.1
Earnings Yield (Greenblatt) 3.20
NUVA's Earnings Yield (Greenblatt) is ranked higher than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. NUVA: 3.20 )
NUVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 4.8
Current: 3.2
0.6
4.8
Forward Rate of Return (Yacktman) -0.19
NUVA's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. NUVA: -0.19 )
NUVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.1   Max: -0.2
Current: -0.19
-4.1
-0.2

Business Description

Nuvasive Inc, was incorporated in Delaware in July 1997. It is a medical device company focused on developing minimally disruptive surgical products and procedures for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery, including biologics. The Company's main product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as an offering of biologics, cervical, motion preservation products, and Intra-Operative Monitoring (IOM) services. Its spine surgery product line offerings, which include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings still under development, are mainly used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings include allograft, (donated human tissue) — Triad , and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, FormaGraft, a collagen synthetic product used to aid the fusion process, and AttraX, a synthetic bone graft material, which is still in the process of U.S. regulatory clearance, to aid in spinal fusion. Its MAS platform, with the unique advantages provided by its nerve monitoring systems, enables an innovative lateral procedure known as eXtreme Lateral Interbody Fusion, or XLIF, in which surgeons access the spine for a fusion procedure from the side of the patient's body, rather than from the front or back. Its MaXcess instruments provide access to the spine in a manner that affords direct visualization and its nerve monitoring systems allow surgeons to avoid critical nerves. Its cervical product offering now provides a full set of solutions for cervical fusion surgery, including both allograft and CoRoent implants, as well as cervical plating and posterior fixation products, and a set of motion preservation product offerings still under development. The Company competes with Medtronic Sofamor Danek (Medtronic), Natus, Cadwell Laboratories, and VIASYS Healthcare, a division of CareFusion Corporation DePuy, Stryker Spine and Synthes, Inc. The Companies products are medical devices and tissues subject to regulation by the FDA and other regulatory bodies.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:NK8.Germany
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
Vanguard Health Care Fund Buys NVS, AMGN, BMY, UTHR, TEVA, VHS, THC, Sells CEPH, VRTX, NUVA Aug 03 2011 
Vanguard Health Care Fund Buys ACL, NUVA, SLXP, DF, VRTX, AMGN, ZMH, Sells ENR, GENZ, NVS Feb 01 2011 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: SAY, VRX, THOR, SVU, NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: ASIA, SAY, VRX, AMLN, NUVA Jan 01 2011 
Three Stocks for 2011: NUVA, ENOC, CBK Nov 25 2010 
NuVasive Inc. Reports Operating Results (10-Q) Nov 05 2010 
NuVasive Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Our Partners
UPDATE: Barrington Raises PT on NuVaisve on Multiple Positive Factors May 21 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial